PFM Health Sciences LP Trims Stock Holdings in Humana Inc. (NYSE:HUM)

PFM Health Sciences LP reduced its stake in Humana Inc. (NYSE:HUM) by 18.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,954 shares of the insurance provider’s stock after selling 23,386 shares during the quarter. Humana comprises approximately 1.8% of PFM Health Sciences LP’s portfolio, making the stock its 21st biggest holding. PFM Health Sciences LP owned approximately 0.08% of Humana worth $32,293,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. FMR LLC lifted its position in shares of Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares in the last quarter. Pzena Investment Management LLC lifted its position in Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after buying an additional 187,903 shares during the period. Davis Selected Advisers lifted its position in Humana by 16.1% during the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after buying an additional 321,233 shares during the period. Marshall Wace LLP lifted its position in Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after buying an additional 774,085 shares during the period. Finally, Legal & General Group Plc lifted its position in Humana by 2.1% during the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock worth $442,396,000 after buying an additional 24,842 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

HUM stock opened at $296.78 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $504.79. The firm has a market cap of $35.74 billion, a P/E ratio of 26.29, a price-to-earnings-growth ratio of 2.34 and a beta of 0.52. The stock has a 50-day simple moving average of $275.33 and a 200-day simple moving average of $329.47.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. On average, equities analysts predict that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a yield of 1.19%. Humana’s dividend payout ratio (DPR) is presently 31.36%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. KeyCorp assumed coverage on Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 target price on shares of Humana in a research report on Tuesday, October 1st. UBS Group reduced their target price on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, Barclays raised their price objective on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Humana has a consensus rating of “Hold” and an average price target of $315.86.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.